<SEC-DOCUMENT>0001104659-17-023662.txt : 20170417
<SEC-HEADER>0001104659-17-023662.hdr.sgml : 20170417
<ACCEPTANCE-DATETIME>20170417080610
ACCESSION NUMBER:		0001104659-17-023662
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170411
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170417
DATE AS OF CHANGE:		20170417

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Xencor Inc
		CENTRAL INDEX KEY:			0001326732
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				201622502
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36182
		FILM NUMBER:		17763586

	BUSINESS ADDRESS:	
		STREET 1:		111 WEST LEMON AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016
		BUSINESS PHONE:		626-305-5900

	MAIL ADDRESS:	
		STREET 1:		111 WEST LEMON AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a17-11317_18k.htm
<DESCRIPTION>8-K
<TEXT>


<html>
<head>



  </head>
<body link=blue lang="EN-US">
<div style="font-family:Times New Roman;">
<div style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 3.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED STATES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">WASHINGTON, D.C. 20549</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade align="center" style="color:black;"></div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM&nbsp;8-K</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade align="center" style="color:black;"></div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">CURRENT REPORT</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">Pursuant to Section&nbsp;13 or 15(d)</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">of the Securities Exchange Act of 1934</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date of Report (Date of earliest event reported):<b> April&nbsp;11, 2017</b></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade align="center" style="color:black;"></div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">XENCOR,&nbsp;INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Exact name of registrant as specified in its charter)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade align="center" style="color:black;"></div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Delaware</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">001-36182</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">20-1622502</font></b></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(State of   incorporation)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Commission File No.)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(IRS Employer   Identification No.)</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">111 West Lemon Avenue</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Monrovia, California 91016</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address of principal executive offices and zip code)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Registrant&#146;s telephone number, including area code:<b> (626)&nbsp;305-5900</b></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade align="center" style="color:black;"></div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Check the appropriate box below if the Form&nbsp;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font>Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17 CFR 240.14d-2(b))</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c))</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&nbsp;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&nbsp;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Emerging growth company&nbsp;</font><font face="Wingdings">o</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a)&nbsp;of the Exchange Act.&nbsp;</font><font face="Wingdings">o</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="border-bottom:solid windowtext 3.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\109769\17-11317-1\task8382200\11317-1-ba.htm',USER='109769',CD='Apr 15 04:06 2017' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 5.02&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b>&nbsp;On April&nbsp;11, 2017, Robert F. Baltera,&nbsp;Jr. provided notice to the board of directors (the &#147;Board&#148;) of Xencor,&nbsp;Inc. (the &#147;Company&#148;) of his intent not to stand for reelection at the Company&#146;s 2017 Annual Meeting of Stockholders.&#160; Mr.&nbsp;Baltera&#146;s intent not to stand for reelection is not the result of a disagreement with the Company on any matter relating to the Company&#146;s operations, policies or practices.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(d)</font></b>&nbsp;On April&nbsp;14, 2017, Kevin C. Gorman, Ph.D., was appointed to the Board.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In accordance with the Company&#146;s amended and restated non-employee director compensation policy, Dr.&nbsp;Gorman is entitled to receive an initial grant consisting of a nonstatutory stock option to purchase 15,000 shares of the Company&#146;s common stock (the &#147;Common Stock&#148;), one-third of which shares will vest on the one year anniversary of the grant date and the balance of the shares will vest in a series of 24 equal monthly installments thereafter, such that the option is fully vested on the third anniversary of the date of grant, subject to Dr.&nbsp;Gorman&#146;s continuous service through each such vesting date. Dr.&nbsp;Gorman will also be entitled to receive a $40,000 annual cash retainer for service as director, and will be eligible to receive additional equity compensation in the future. Dr.&nbsp;Gorman will enter into the Company&#146;s standard form of indemnification agreement. The Company is not aware of any transaction involving Dr.&nbsp;Gorman requiring disclosure under Item 404(a)&nbsp;of Regulation S-K.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:2.25pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On April&nbsp;17, 2017, the Company issued a press release announcing Mr.&nbsp;Baltera&#146;s notice of his intent not to stand for reelection and the appointment of Dr.&nbsp;Gorman to the Board, a copy of which is attached hereto as Exhibit&nbsp;99.1.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 9.01</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Financial Statements and Exhibits.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Exhibits</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exhibit&nbsp;No.</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="85%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:85.66%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.84%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="85%" valign="bottom" style="padding:0in 0in 0in 0in;width:85.66%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Press Release of   Xencor,&nbsp;Inc. dated April&nbsp;17, 2017.</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="PB_2_145450_8811"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\109769\17-11317-1\task8382200\11317-1-ba.htm',USER='109769',CD='Apr 15 04:06 2017' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIGNATURES</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date: April&nbsp;17,   2017</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">XENCOR,&nbsp;INC.</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="46%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:46.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Bassil I. Dahiyat,   Ph.D.</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Bassil I. Dahiyat,   Ph.D.</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">President and Chief   Executive Officer</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="PB_3_145638_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\109769\17-11317-1\task8382200\11317-1-ba.htm',USER='109769',CD='Apr 15 04:06 2017' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INDEX TO EXHIBITS</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="11%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exhibit&nbsp;No.</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="85%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:85.84%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description</font></b></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="85%" valign="top" style="padding:0in 0in 0in 0in;width:85.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Press Release of   Xencor,&nbsp;Inc. dated April&nbsp;17, 2017.</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">4<a name="PB_4_145710_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\109769\17-11317-1\task8382200\11317-1-ba.htm',USER='109769',CD='Apr 15 04:06 2017' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a17-11317_1ex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>


<html>
<head>




  </head>
<body link=blue lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 99.1</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><img width="219" height="55" src="g113171mmi001.gif"></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Xencor Appoints Kevin Gorman, Ph.D., to its Board of Directors</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Monrovia, Calif. &#151; April&nbsp;17, 2017</font></b> &#151;&nbsp;Xencor,&nbsp;Inc.&nbsp;(NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of inflammation and cancer, today announced that Kevin Gorman, Ph.D., chief executive officer of Neurocrine Biosciences, has been appointed to Xencor&#146;s Board of Directors. Xencor also announced that Robert Baltera,&nbsp;Jr., who has served as director since 2013, will not stand for re-election at the 2017 Annual Meeting of Stockholders.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;Kevin is a great addition to Xencor&#146;s Board as we plan our next phase of growth,&#148; said Bassil Dahiyat, Ph.D., president and chief executive officer of Xencor. &#147;His substantial experience building successful biotechnology companies, taking drugs from clinical development to FDA approval, and preparing for commercialization will be invaluable as we progress our drug candidates into later stages of development, and I&#146;m excited to work with him.&#148;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dr.&nbsp;Gorman, Ph.D. is a founder of Neurocrine Biosciences. Prior to assuming his current role as CEO, he served as Neurocrine&#146;s chief operating officer after having served as executive vice president and chief business officer and senior vice president of business development. From 1990 until joining Neurocrine in 1993, Dr.&nbsp;Gorman was a principal of Avalon Medical Partners, L.P. where he contributed to the founding of Neurocrine and several other biotechnology companies, including Onyx Pharmaceuticals, Metra Biosystems,&nbsp;IDUN and ARIAD Pharmaceuticals. Dr.&nbsp;Gorman received his Ph.D. in Immunology and M.B.A. in Finance from the University of California, Los Angeles and did further post-doctoral training at The Rockefeller University.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;Xencor has developed a powerful antibody engineering technology, a deep pipeline of antibody drug candidates, and promising bispecific antibodies that create tremendous opportunity for bringing novel medicines to patients,&#148; said Dr.&nbsp;Gorman. &#147;I am looking forward to joining the Xencor Board and contributing to the Company&#146;s continued growth.&#148;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dr.&nbsp;Dahiyat continued, &#147;On behalf of Xencor&#146;s Board of Directors and management team,&nbsp;I want to thank Bob for his many contributions. Bob&#146;s guidance played a key role in enabling Xencor to expand our clinical development pipeline and advance to where we are today, and I wish him well as he focuses on launching his new company.&#148;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About Xencor,&nbsp;Inc.</font></b><br> Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer. Currently, 11 candidates engineered with Xencor&#146;s XmAb&#174; technology are in clinical development internally and with partners. Xencor&#146;s internal programs include: XmAb&#174;5871 in Phase 2 development for the treatment of IgG4-Related Disease, and also for the treatment of Systemic Lupus Erythematosus; XmAb&#174;7195 in Phase 1 development for the treatment of asthma and allergic diseases; XmAb&#174;14045 in Phase 1 development for acute myeloid leukemia; XmAb&#174;13676 in Phase 1 development for B-cell malignancies; and XmAb&#174;18087 for the treatment of neuroendocrine tumors, in pre-clinical development. Xencor&#146;s XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action.&#160; Xencor partners include Novartis, Amgen, MorphoSys, Merck, CSL/Janssen, Alexion and Boehringer Ingelheim. For more information, please visit www.xencor.com.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\109753\17-11317-1\task8382162\11317-1-mm.htm',USER='109753',CD='Apr 15 03:27 2017' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Forward Looking Statements:</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Statements contained in this press release regarding matters that are not historical facts are forward-looking statements within the meaning of applicable securities laws, including any expectations relating to Xencor&#146;s Board composition and future growth trajectory. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements and the timing of events to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. Such risks include, without limitation, the risks associated with the process of discovering, developing, manufacturing and commercializing drugs that are safe and effective for use as human therapeutics and other risks described in Xencor&#146;s public securities filings. All forward-looking statements are based on Xencor&#146;s current information and belief as well as assumptions made by Xencor. Readers are cautioned not to place undue reliance on such statements and Xencor disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.16%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Investor Contact: </font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">John Kuch, Vice President   Finance, Xencor </font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Tel: 626-737-8013 </font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">jkuch@xencor.com</font></p>    </td>
<td width="55%" valign="top" style="padding:0in 0in 0in 0in;width:55.84%;">
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Corporate Communications   Contact:</font></b><b> </b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Jason I. Spark </font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Canale Communications for Xencor </font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Tel: 619-849-6005 </font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">jason@canalecomm.com</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\109753\17-11317-1\task8382162\11317-1-mm.htm',USER='109753',CD='Apr 15 03:27 2017' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g113171mmi001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g113171mmi001.gif
M1TE&.#=AVP W '<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
M    VP W (?___\I6FLA4FL0M;TQ8W/>WN:UO;WW]_>]Q=Y:G,ZEG*VM:ZWF
M:^_F:VOF$._F$&OF:ZWF:RGF$*WF$"FM:^^M:VNM$.^M$&NM:RFM$*VM$"FM
M:XSF:\[F:TKF$,[F$$KF:XSF:PCF$(SF$ BM:\ZM:TJM$,ZM$$JM:PBM$(RM
M$ @QSM:]YN9[:UHI.EI[*5I[:QDI.AE[*1E[:YPI$%I2*5I2:QDI$!E2*1E:
M[YP0[]X0:YQ::]Y:[UH0:]X0[UI:*=X0*=Y:K5H0K5H0[YQ:[QD0[QE:*9P0
M*9Q:K1D0K1E22EI24IQ[SIP0C-XQC)Q[2EH(.EI["%I[2AD(.AE["!E[2IP(
M$%I2"%I22AD($!E2"!D02IQ:2MY:SEH02MX0SEI:"-X0"-Y:C%H0C%H0SIQ:
MSAD0SAE:")P0")Q:C!D0C!E:A(R<M;VEQ>:<YN8Q:YPI8T(I8Q (8T((8Q#F
MG._FG&OF0N_F0FOFG*WFG"GF0JWF0BFMG.^MG&NM0N^M0FNMG"FM0JVM0BE:
MI9Q:G.^MG(Q[G,[FG,[FG$KF0L[F0DKFG(SFG CF0HSF0@BMG,ZMG$JM0LZM
M0DJMG BM0HRM0@C6[U*<[U+6[QF<[QF<[XS6Q5*<Q5+6Q1F<Q1F<Q8Q[I9Q[
MQ=Y":W/F[^8QK=Y[E*5[:]Y[[UHQ[]XQ:]XQ[UI[*=XQ*=Y[K5HQK5I[[YPQ
M[YQ[[QDQ[QE[*9PQ*9Q[K1DQK1DQ2IPQC-Y[2MY[SEHQ2MXQSEI["-XQ"-Y[
MC%HQC%HQSIQ[SADQSAE[")PQ")Q[C!DQC!GF[_?FO>;6[[6<YKW6[X1*<X36
MQ;76Q81[G.]:Q<[W[U*][U+W[QF][QF][XSWQ5*]Q5+WQ1F]Q1F]Q8Q[YLYS
MC)1:[^]:SJU2:U):[\Y:SHP(E*T(E(SW[[6]YKWW[X3WQ;7WQ800SLX0K<XI
MK:U:C*5[YN\0:VL0K>]:Q>\0SN\QK8Q2<ZT(M9S_UN8I4G,(4FLI4F,Q4F,A
M4F/__^8A4G,I6F,(_P !"!Q(L*#!@P@3*ES(L*'#AQ C2IQ(L:+%BQ@S:MS(
ML:/'A\G>B)/6+=G'DRA3JERYD(6T 0/8#1#'@J7-FSAS0NRV N:Z >W>'=!)
MM*C1E =XV@,*<T#)HU"C2I7XYB6[=NNPLNLV=*K7KV!=^H2YHAVX-V#3JE5Y
MX$"R9&Z["NR&%6C/I>],KMW+]^*!-SU_"F[:$R;6=@/62:O9M[%CAP=$%3YL
M.#'BK#\/HWW,N;-!%F7+L,-<MZQETNM$D?+,VC.IPEF!_K17ERE,>RO>R$WH
MEE0RW\!W'_Q-'#C" Z0*L"A :C7&Y,R=0VRK/+K>B;\+:&_^/#K% PK8./]K
MLQIY6=2791_.G%HZ0E)M1A&8+Y_ J#;"![+PMF^^_U'>%$0* H2,PL^!_/A#
M@#?D)50="\JPP()S\#E#P($*>F- ?@>QH("%_.R3( '.F() /Y 5T(8SH_B#
MX7P,,G80*1!*&*%S"(#H#QL4A4* /__P0\"& /"$F&'LJ<<>5MV0PB%!\848
MHHOWS6C*@02(N,\^SLAX0(X'BD@ /D)BB$\H[@WD#8)AMI&, <X@>.&%^9"(
M0)H$%>!CG65>*.(_.QJ )T$'*$/(G/P$24"0+H;HC8P#]8- HB(**6@;_P29
MX"C7/<2"@8KZXXYSW9R&Y&6(U8;8"BP\.5 !5R+_ZJ([)Q)$B@'X7 CDCZ,@
M(!!RDQZ8ZX'_7"ADIO@$:) [(69ZH %M_%@FD&4F.@JD QW  AM:)NHBHKH2
MT(9""!A8J:S&^K,//L[4^NN7B29:+ )M8%FF,Q(=X,V/@&KJZU LO-&-* )W
M8_# XJQ7&TU#N9HCD$#^(V(H!>3)QH69?AM*I B .V*"TY9I2IH7][F/.\9B
M?*R8+K*!+0 %L$$FN(R6Z2P<!G3ZZSEL% MHNL[.*3$_50+0, )!"^G./A!C
M.4I$I)@RL\T$N L BE<;+1<IXIS:5$FN&AUMIHCRXTT!0\'ZHI +=G6KRBDG
M:BS9"?[C3D%K5NMGRDT;_ZNE M(=$'.(<>_J;;\A=KG;FW&Z6&R?>M<-:+O9
M&D  GYK2K2N^$'6,J*+[M.H0*2_%%AL[XL"E4-00]ZM@*&U9?FR\O0Y$BC/?
MVDLB&^Z &#<_;6 -P+Z 3EO\HK,+[6*74!I8-HGNF%+RH@I*/#)!+#!+;<H:
MLF" *2TJJBD;;1G-PM!"%X^E?6$+""++03;XZT)_@>-3;=+H-K]!VH+X>(+C
M<8.!ZO8C FQ,(,FHU^%>YQX$L,%>_,C5=9AEO,>YPP L0$ H< <Y!1$) "QH
MW.'N(YW]P(T?SC" T8RF #%-BPT(V T+0@$RC VI80:(W*X,B(#E#"HA/L)2
MJ/^N%Q' -*4=*V ';O27D'Z$,&YSFL^Q&N4-Z=P.<D.:$<JP)*)Q"81X6+R3
MK?9U.!$1,3[]N9<*!10MZAW(%!4[P#F8A3%UN6Q&T=*=,\ISOMR5:504Z5@:
MJT6('S*D&]*P1U84"9/%-.PXLE,9/H*D*+E5L6%O<IR"#.B@LOF#4P)YH(+B
M537AV<Y_<QJ9X$2IJ%YQJ !K,AP,!0*)N/VC7:;,DRF.)R3\',  $3/<'BL"
MHBD2+884(=U8;$.3A20CB 7L$^)P1I!GEFV8"3%%RC+EJ^$A[UC8-,C8<N>.
MBL'I6&0JY'':N"@"4),4H1!?.@TI*5FAT#?GP^(:)1+_M=]=2'X4 <VJ:C,
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M;1!:?Z=I"!1/WU(\E(,<PI4\>A,TW300D*8^.Z<?<^<M=<=J+ 0'V^10^4<
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H!&(A%89WV9=1*479=H%^.9C?>#51$B2Y1IB*B109Y"2+^9@2$1  .P$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
